3 Biotech Stocks That Actually Pay Dividends and Keep Raising Them

Impact · against what's priced in

The article provides no material catalyst for Regeneron or Amgen, as its primary positives—the Sanofi payment and strong Q3 growth—and primary risks—Eylea erosion—are already factored into current valuations. Sanofi remains positively associated with Regeneron's growth, though the impact is incremental.

AMGN+0.00

Already priced in

The price assumes

The ongoing erosion of legacy products Enbrel (-33%), Prolia (-34%), and Xgeva (-6%) is already absorbed.